Methylation markers of malignant potential in meningiomas

Laboratory investigation

View More View Less
  • 1 Division of Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas;
  • 2 Brain Tumor and Neuro-oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center, Case Western Reserve School of Medicine;
  • 3 Case Comprehensive Cancer Center,
  • 4 Department of Neurosurgery, Center for Translational Neuroscience, and
  • 5 Department of Pathology, Case Western Reserve University School of Medicine;
  • 6 Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Department of Neurosurgery, Neurological and Taussig Cancer Institute, Cleveland Clinic, Cleveland;
  • 7 Brain Tumor Center at the University of Cincinnati Neuroscience Institute, and Department of Neurosurgery, University of Cincinnati College of Medicine, and Mayfield Clinic, Cincinnati, Ohio;
  • 8 Institute for the Neurosciences, Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts; and
  • 9 Dardinger Neuro-Oncology Center, Department of Neurosurgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

Although most meningiomas are benign, about 20% are atypical (Grade II or III) and have increased mortality and morbidity. Identifying tumors with greater malignant potential can have significant clinical value. This validated genome-wide methylation study comparing Grade I with Grade II and III meningiomas aims to discover genes that are aberrantly methylated in atypical meningiomas.

Methods

Patients with newly diagnosed meningioma were identified as part of the Ohio Brain Tumor Study. The Infinium HumanMethylation27 BeadChip (Illumina, Inc.) was used to interrogate 27,578 CpG sites in 14,000 genes per sample for a discovery set of 33 samples (3 atypical). To verify the results, the Infinium HumanMethylation450 BeadChip (Illumina, Inc.) was used to interrogate 450,000 cytosines at CpG loci throughout the genome for a verification set containing 7 replicates (3 atypical), as well as 12 independent samples (6 atypical). A nonparametric Wilcoxon exact test was used to test for difference in methylation between benign and atypical meningiomas in both sets. Heat maps were generated for each set. Methylation results were validated for the 2 probes with the largest difference in methylation intensity by performing Western blot analysis on a set of 20 (10 atypical) samples, including 11 replicates.

Results

The discovery array identified 95 probes with differential methylation between benign and atypical meningiomas, creating 2 distinguishable groups corresponding to tumor grade when visually examined on a heat map. The validation array evaluated 87 different probes and showed that 9 probes were differentially methylated. On heat map examination the results of this array also suggested the existence of 2 major groups that corresponded to histological grade. IGF2BP1 and PDCD1, 2 proteins that can increase the malignant potential of tumors, were the 2 probes with the largest difference in intensity, and for both of these the atypical meningiomas had a decreased median production of protein, though this was not statistically significant (p = 0.970 for IGF2BP1 and p = 1 for PDCD1).

Conclusions

A genome-wide methylation analysis of benign and atypical meningiomas identified 9 genes that were reliably differentially methylated, with the strongest difference in IGF2BP1 and PDCD1. The mechanism why increased methylation of these sites is associated with an aggressive phenotype is not evident. Future research may investigate this mechanism, as well as the utility of IGF2BP1 as a marker for pathogenicity in otherwise benign-appearing meningiomas.

Abbreviations used in this paper:OBTS = Ohio Brain Tumor Study; UHCMC = University Hospitals Case Medical Center.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address correspondence to: Jill S. Barnholtz-Sloan, Ph.D., Case Comprehensive Cancer Center, CWRU School of Medicine, 11100 Euclid Ave., Wearn 152, Cleveland, OH 44106-5065. email: jsb42@case.edu.

Please include this information when citing this paper: published online August 9, 2013; DOI: 10.3171/2013.7.JNS13311.

  • 1

    Al-Mefty O, , Kadri PA, , Pravdenkova S, , Sawyer JR, , Stangeby C, & Husain M: Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210218, 2004

    • Search Google Scholar
    • Export Citation
  • 2

    Aydemir F, , Yurtcu E, , Balci TB, , Sahin FI, , Gulsen S, & Altinors N: Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients. Genet Test Mol Biomarkers 16:335340, 2012

    • Search Google Scholar
    • Export Citation
  • 3

    Barski D, , Wolter M, , Reifenberger G, & Riemenschneider MJ: Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20:623631, 2010

    • Search Google Scholar
    • Export Citation
  • 4

    Bibikova M, , Lin Z, , Zhou L, , Chudin E, , Garcia EW, & Wu B, : High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16:383393, 2006

    • Search Google Scholar
    • Export Citation
  • 5

    Blank C, , Gajewski TF, & Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54:307314, 2005

    • Search Google Scholar
    • Export Citation
  • 6

    Bock C: Analysing and interpreting DNA methylation data. Nat Rev Genet 13:705719, 2012

  • 7

    Dolecek TA, , Propp JM, , Stroup NE, & Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:Suppl 5 v1v49, 2012

    • Search Google Scholar
    • Export Citation
  • 8

    Drummond KJ, , Zhu JJ, & Black PM: Meningiomas: updating basic science, management, and outcome. Neurologist 10:113130, 2004

  • 9

    Durand A, , Labrousse F, , Jouvet A, , Bauchet L, , Kalamaridès M, & Menei P, : WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95:367375, 2009

    • Search Google Scholar
    • Export Citation
  • 10

    Eichenmüller M, , Gruner I, , Hagl B, , Häberle B, , Müller-Höcker J, & von Schweinitz D, : Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 49:482490, 2009

    • Search Google Scholar
    • Export Citation
  • 11

    Jeffery JM, , Urquhart AJ, , Subramaniam VN, , Parton RG, & Khanna KK: Centrobin regulates the assembly of functional mitotic spindles. Oncogene 29:26492658, 2010

    • Search Google Scholar
    • Export Citation
  • 12

    Kai M, & Wang TS: Checkpoint responses to replication stalling: inducing tolerance and preventing mutagenesis. Mutat Res 532:5973, 2003

    • Search Google Scholar
    • Export Citation
  • 13

    Kishida Y, , Natsume A, , Kondo Y, , Takeuchi I, , An B, & Okamoto Y, : Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33:436441, 2012

    • Search Google Scholar
    • Export Citation
  • 14

    Kline J, & Gajewski TF: Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 11:13541359, 2010

    • Search Google Scholar
    • Export Citation
  • 15

    Laird PW: Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 11:191203, 2010

  • 16

    Lemm I, & Ross J: Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant. Mol Cell Biol 22:39593969, 2002

    • Search Google Scholar
    • Export Citation
  • 17

    Liu Y, , Pang JC, , Dong S, , Mao B, , Poon WS, & Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416425, 2005

    • Search Google Scholar
    • Export Citation
  • 18

    Lusis EA, , Watson MA, , Chicoine MR, , Lyman M, , Roerig P, & Reifenberger G, : Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:71217126, 2005

    • Search Google Scholar
    • Export Citation
  • 19

    Mawrin C, & Perry A: Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379391, 2010

  • 20

    Meyer LR, , Zweig AS, , Hinrichs AS, , Karolchik D, , Kuhn RM, & Wong M, : The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res 41:D64D69, 2013

    • Search Google Scholar
    • Export Citation
  • 21

    Mojtahedi Z, , Mohmedi M, , Rahimifar S, , Erfani N, , Hosseini SV, & Ghaderi A: Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene 508:229232, 2012

    • Search Google Scholar
    • Export Citation
  • 22

    Perry A, , Banerjee R, , Lohse CM, , Kleinschmidt-DeMasters BK, & Scheithauer BW: A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183190, 2002

    • Search Google Scholar
    • Export Citation
  • 23

    Perry A, , Stafford SL, , Scheithauer BW, , Suman VJ, & Lohse CM: Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:14551465, 1997

    • Search Google Scholar
    • Export Citation
  • 24

    Shahi MH, , Afzal M, , Sinha S, , Eberhart CG, , Rey JA, & Fan X, : Human hedgehog interacting protein expression and promoter methylation in medulloblastoma cell lines and primary tumor samples. J Neurooncol 103:287296, 2011

    • Search Google Scholar
    • Export Citation
  • 25

    Shimada H, , Kuboshima M, , Shiratori T, , Nabeya Y, , Takeuchi A, & Takagi H, : Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 30:97103, 2007

    • Search Google Scholar
    • Export Citation
  • 26

    Smith JL, , Kupchak BR, , Garitaonandia I, , Hoang LK, , Maina AS, & Regalla LM, : Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors. Steroids 73:11601173, 2008

    • Search Google Scholar
    • Export Citation
  • 27

    Stöhr N, , Köhn M, , Lederer M, , Glass M, , Reinke C, & Singer RH, : IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Genes Dev 26:176189, 2012

    • Search Google Scholar
    • Export Citation
  • 28

    Tessema M, , Yu YY, , Stidley CA, , Machida EO, , Schuebel KE, & Baylin SB, : Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 30:11321138, 2009

    • Search Google Scholar
    • Export Citation
  • 29

    Wang W, , Lau R, , Yu D, , Zhu W, , Korman A, & Weber J: PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 21:10651077, 2009

    • Search Google Scholar
    • Export Citation
  • 30

    Weidensdorfer D, , Stöhr N, , Baude A, , Lederer M, , Köhn M, & Schierhorn A, : Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 15:104115, 2009

    • Search Google Scholar
    • Export Citation
  • 31

    Wilkinson K, , Velloso ER, , Lopes LF, , Lee C, , Aster JC, & Shipp MA, : Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102:41874190, 2003

    • Search Google Scholar
    • Export Citation
  • 32

    Woo SR, , Turnis ME, , Goldberg MV, , Bankoti J, , Selby M, & Nirschl CJ, : Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917927, 2012

    • Search Google Scholar
    • Export Citation
  • 33

    Yisraeli JK: VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 97:8796, 2005

Metrics

All Time Past Year Past 30 Days
Abstract Views 463 278 14
Full Text Views 189 24 1
PDF Downloads 128 19 1
EPUB Downloads 0 0 0